Our look is new. Our purpose is the same. Learn more about our brand evolution.
Fulcrum halts losmapimod development by June Kinoshita This morning, we received news Fulcrum has decided to halt its development of losmapimod (see press release below). Fulcrum’s decision was based on […]
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore, […]
A complementary approach for FSHD therapeutics by Justin Cohen, New Haven, Connecticut This is an exciting time for facioscapulohumeral muscular dystrophy (FSHD) patients, with many therapeutics entering clinical trials. Most […]
Results presented by Avidity of interim data from its Phase 1/2 clinical trial in FSHD were all the buzz at this year’s International Research Congress and FSHD Connect conference. […]
